TAVNEOS
Active Ingredient: AVACOPAN
Product Overview
About TAVNEOS
TAVNEOS is a prescription medication containing the active ingredient AVACOPAN, indicated for the treatment of granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) in adults.
Key Benefits & Uses
- Treatment of granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) in adults
- Reduction of proteinuria and hematuria in patients with GPA
- Improvement of renal function in patients with GPA
Active Ingredient & Action
AVACOPAN, the active ingredient in TAVNEOS, is a potent and selective inhibitor of the interleukin-1 beta (IL-1β) receptor. By blocking the IL-1β receptor, AVACOPAN reduces the inflammatory response and prevents tissue damage associated with GPA and EGPA.
Important Notes
TAVNEOS is available in capsule form and should be taken orally once daily. It is essential to follow the prescribed dosage and schedule to ensure optimal efficacy and minimize potential side effects. Patients with a history of hypersensitivity to AVACOPAN or any other component of TAVNEOS should not use this medication. Consult your healthcare provider for more information and to discuss potential interactions with other medications.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.